Payment overview · 2025
General Payments
$305.44
11 reported records · 8 companies
Healthcare provider profile · identity verified
Palak Jitendra Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BROOKINGS, OR · NPI 1922367572
Verified facts
What the public records show
CMS Open Payments records show Palak Jitendra Patel, MD received $305.44 in general payments during 2025 across 11 reported records.
Galderma Laboratories, L.P. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $99.41 | 32.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.61 | 17.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.73 | 11.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.57 | 10.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.06 | 9.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.43 | 7.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.81 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.82 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.44 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DYSPORT Normalized: dysport |
Drug | Galderma Laboratories, L.P. | $83.36 | 1 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma US Inc | $53.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 32 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 125 |
| Losartan Potassium | Losartan Potassium | 350 | 120 |
| Lisinopril | Lisinopril | 344 | 115 |
| Metformin Hcl | Metformin Hcl | 262 | 86 |
| Potassium Chloride | Potassium Chloride | 252 | 84 |
| Furosemide | Furosemide | 241 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 73 |
| Gabapentin | Gabapentin | 222 | 73 |
| Omeprazole | Omeprazole | 213 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 71 |
| Xarelto | Rivaroxaban | 207 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 58 |
| Carvedilol | Carvedilol | 162 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 39 |
| Trazodone Hcl | Trazodone Hcl | 126 | 44 |
| Famotidine | Famotidine | 125 | 51 |
| Eliquis | Apixaban | 124 | 47 |
| Liothyronine Sodium | Liothyronine Sodium | 124 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 34 |
| Jardiance | Empagliflozin | 111 | 34 |
| Finasteride | Finasteride | 105 | 28 |
| Montelukast Sodium | Montelukast Sodium | 98 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 33 |
| Donepezil Hcl | Donepezil Hcl | 88 | 19 |
| Simvastatin | Simvastatin | 88 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 17 |
| Mirtazapine | Mirtazapine | 77 | 26 |
| Estradiol | Estradiol | 76 | 23 |
| Spironolactone | Spironolactone | 76 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 20 |
| Prednisone | Prednisone | 74 | 40 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 21 |
| Buspirone Hcl | Buspirone Hcl | 64 | 21 |
| Progesterone | Progesterone, Micronized | 63 | 21 |
| Celecoxib | Celecoxib | 61 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 38 |
| Sertraline Hcl | Sertraline Hcl | 60 | 19 |
| Tramadol Hcl | Tramadol Hcl | 59 | 26 |
| Alendronate Sodium | Alendronate Sodium | 55 | 15 |
| Allopurinol | Allopurinol | 51 | 18 |
| Metformin Hcl Er | Metformin Hcl | 49 | 20 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Atenolol | Atenolol | 43 | 16 |
| Synthroid | Levothyroxine Sodium | 43 | 15 |
| Warfarin Sodium | Warfarin Sodium | 43 | 15 |
| Nystatin | Nystatin | 42 | 23 |
| Ozempic | Semaglutide | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 41 | 14 |
| Glimepiride | Glimepiride | 40 | 13 |
| Glipizide | Glipizide | 39 | 13 |
| Pregabalin | Pregabalin | 39 | 18 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Propranolol Hcl | Propranolol Hcl | 38 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 13 |
| Lorazepam | Lorazepam | 35 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Fluconazole | Fluconazole | 31 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 11 |
| Testosterone | Testosterone | 30 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Mupirocin | Mupirocin | 28 | 23 |
| Digoxin | Digoxin | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | 11 |
| Alprazolam | Alprazolam | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | 11 |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Valsartan | Valsartan | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 11 |
| Nadolol | Nadolol | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.44 · 11 records | Galderma Laboratories, L.P. | AIRSUPRA, DYSPORT, Izervay, JARDIANCE, LEQVIO, OTEZLA, REPATHA, TRELEGY ELLIPTA, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error